Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & Cumberland Pharmaceuticals (NASDAQ:CPIX)

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Insider & Institutional Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cumberland Pharmaceuticals has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its share price is 196,142% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and Eloxx Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.30 million	2.37	-$2.84 million	($0.71)	-9.86
Eloxx Pharmaceuticals	$6.36 million	8.82	-$5.99 million	($1.54)	-9.02

Cumberland Pharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cumberland Pharmaceuticals and Eloxx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1	0	0	0	1.00
Eloxx Pharmaceuticals	1	0	2	2	3.00

Eloxx Pharmaceuticals has a consensus price target of $38.33, suggesting a potential upside of 175.98%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Profitability

This table compares Cumberland Pharmaceuticals and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Summary

Eloxx Pharmaceuticals beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.